Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26938749 | 0.92 | POLB (0.44) | KMT2AMEN1CYP2C9BRD4SIRT1 | |
| SCHEMBL24377969 | 0.90 | SIRT1 (0.50) | DGAT1SOAT2CYP2C9SOAT1DGAT2 | |
| SCHEMBL26938745 | 0.85 | SIRT1 (0.51) | KMT2AMEN1SIRT1 | |
| SCHEMBL26938724 | 0.85 | SIRT1 (0.51) | KMT2AMEN1SIRT1 | |
| SCHEMBL26938740 | 0.85 | SIRT1 (0.51) | KMT2AMEN1SIRT1 | |
| SCHEMBL26938734 | 0.82 | CASP2 (0.47) | KMT2AMEN1BRD4SIRT1POLB | |
| SCHEMBL24378019 | 0.81 | SIRT1 (0.48) | SIRT1POLBUSP30 | |
| SCHEMBL26938816 | 0.79 | BRD4 (0.43) | KMT2AMEN1BRD4SIRT1POLB | |
| SCHEMBL26938736 | 0.79 | TSHR (0.38) | KMT2AMEN1CYP2C9POLB | |
| SCHEMBL26938741 | 0.79 | TP53 (0.47) | KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | DGAT1 2284/4885KMT2A 464/4885SOAT2 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.